11th Nov 2020 14:54
Beximco Pharmaceuticals PLC - Bangladesh-based medicine manufacturer - Revenue in year ended June 30 jumps 13% to BDT22.61 billion, about GBP228.6 million, from BDT22.82 billion. Pretax profit rises 18% to BDT4.65 billion from BDT3.95 billion. "Despite facing unprecedented operational and logistical challenges as a direct result of the COVID-19 pandemic during the financial year, we have remained focused on executing against our strategy to deliver revenue growth of over 12%, expand our product portfolio and strengthen our position in key markets," Managing Director Nazmul Hassan said.
Current stock price: 72.50 pence
Year-to-date change: up 58%
By Eric Cunha; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Beximco Pharma